From treating depression to helping manage alcohol addiction, researchers say legal medical “magic mushrooms” have many potential benefits.
Soft lighting. Comfortable furniture. Art decorating the walls.
To the untrained eye, this setting appears to be a living room. But it’s not. It’s a research facility specially designed to evoke comfort and ease.
A psilocybin therapy session is taking place.
On the couch lies a patient. They have eye shades and headphones on. Gentle music is playing. Two members of the research team are present to help guide the session over the course of eight hours. Much of this time will be spent in quiet introspection.
Trained medical staff are on-site, should anything unexpected happen.
Despite the trappings of normalcy, this therapy session is anything but.
Psilocybin, the active ingredient found in “magic” mushrooms, or “shrooms,” is a powerful psychedelic.
Despite being about 100 times less potent than LSD, it’s capable of altering perception of space and time, causing visual distortions, euphoria, and mystical experiences.
Unlike marijuana, which has seen a dramatic shift both in terms of support of legalization and recognized therapeutic uses, or MDMA, which has grabbed headlines in recent years for its potential to treat PTSD (some researchers believe the drug could see Food and Drug Administration approval as soon as 2021), psilocybin lacks the same degree of cultural cachet.
And one could be forgiven for thinking of “shrooms” as nothing more than a remnant of the excess of the psychedelic 1960s.
But make no mistake: Psilocybin has a number of potential medical benefits.
Research has shown psilocybin to have potential to treat a range of psychiatric and behavioral disorders, although it’s yet to receive FDA approval for anything.
Its potential indications include depression, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, cluster headaches, and cancer-related or other end-of-life psychological distress.
High-profile initiatives have also popped up in recent months in Denver, Colorado, and Oregon to decriminalize psilocybin mushrooms.
However, experts say they’re unlikely to pass.
Psilocybin mushrooms remain a Schedule I drug according to the Drug Enforcement Agency, meaning they’re classified as having “no currently accepted medical use and a high potential for abuse.”
Other Schedule I drugs include marijuana, MDMA, and LSD.
Yet, despite social stigma and legal red tape, researchers are forging ahead with clinical trials for FDA approval.
Dr. George R. Greer, co-founder and president of the Heffter Research Institute, a non-profit research center that focuses on the therapeutic uses of psychedelics, particularly psilocybin, explains his motivations:
“Our mission is two-fold: one to do research that helps us understand the mind, the brain, how all that works, and number two, to help reduce suffering through therapeutic use of psychedelics.”
The institute is currently focused on two main areas of psilocybin research: addiction and cancer-related psychiatric disorders. Cancer-related psilocybin therapy is considered one of the most promising areas of research for the drug.
However, considering the vast number of potential indications for psilocybin, it’s important to keep in mind that the amount of research also varies widely, from single pilot studies to phase II or III approval trials by the FDA.
Here’s what the current research says about psilocybin treatment for some potential indications.
Depression is among the most researched indications for psilocybin therapy. As Healthline previously reported last year, psilocybin therapy was given “breakthrough therapy” designation (a review fast track) by the FDA for the treatment of depression.
The Usona Institute, a psychedelic research center, is currently in the planning stages of their phase III trial, which will likely begin this year.
Smoking cessation and other addictions
In a small
Matthew Johnson, PhD, associate professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine, led that study.
According to him, psilocybin also has potential to treat other substance use disorders, including alcohol and cocaine addiction.
“The general idea is that the nature of these disorders is a narrowed mental and behavioral repertoire,” he told Healthline. “So, [psilocybin] in well-orchestrated sessions [has] the ability to essentially shake someone out of their routine to give a glimpse of a larger picture and create a mental plasticity with which people can step outside of those problems.”
In fact, a small
Researchers in Alabama are also currently conducting trials for psilocybin therapy on cocaine addiction.
Cancer-related psychological distress
“There’ve been some promising preliminary results in such areas such as the treatment of overwhelming existential anxiety in people who are facing the end of life,who have diagnoses of advanced-stage cancer,” Dr. Charles Grob, professor of psychiatry at the UCLA David Geffen School of Medicine, told Healthline.
Grob, who’s also affiliated with the Heffter Research Institute, has studied psilocybin extensively and authored research on the subject, including, among other things,
A randomized, double-blind trial from Johns Hopkins in 2016 found that a single dose of psilocybin substantially improved quality of life and decreased depression and anxiety in people with life-threatening cancer diagnoses.
“The thing that we have the most evidence for is cancer-related depression and anxiety. That seems really strong, and I’d be surprised if those results didn’t hold up,” Johnson said, who was part of that research.
Despite promising research, there’s no realistic timeline for when, or if, psilocybin will ever be approved by the FDA.
All three experts interviewed by Healthline stress that the substance can be dangerous for a host of different reasons if administered incorrectly.
“It will only be administered in a clinic by specially trained and certified therapists, physicians. It’s never gonna be available out on the street where people can sell it or take too much, or take too many of their pills from a prescription,” Greer said.
Psilocybin affects the cardiovascular system and can lead to increased blood pressure or irregular heartbeat.
It also has the potential to cause serious and permanent psychological problems.
“Psilocybin is a lot more psychologically dangerous than cannabis, and it’s especially dangerous for a small percentage of the population who have had an episode of psychosis or mania, manic episode, or even, say, a close family member whose had those problems, because it can trigger a psychosis or manic episode in a person who is vulnerable to that,” Greer said.
And there’s always the chance of a “bad trip,” or negative experience while taking the drug. There are rare but documented cases of individuals jumping to their deaths or otherwise behaving erratically in such a way that endangers themselves or those around them.
As Grob puts it: “Taken in uncontrolled settings, honestly, all bets are off. You don’t know what you’re gonna get.”
But psilocybin therapy is nothing like taking shrooms at a party. It’s meant to be a meticulously controlled environment to ensure that nothing unexpected happens.
“You name the risk, and we have really good mechanisms for addressing it,” Johnson said.
He further explained, “There are risks, but they are dramatically reduced in medical research and potentially in approved medical use, and I would argue that those risks and our ability to address them fairs very reasonably compared to many procedures that are routinely used in medicine.”
Nonetheless, the safety and efficacy of psilocybin treatment must still be satisfactorily proved to the FDA, which, thus far, it has not.
While some are optimistic that psilocybin may follow in the footsteps of MDMA therapy and potentially even have approval within the next 5 to 10 years, its pathway is far from clear and very uncertain.
When asked if there’s a realistic timeline for approval, Grob told Healthline, “I don’t think so. Even though the research we’re talking about has by and large been very positive and encouraging, there hasn’t been enough research.”
“There needs to be more FDA-approved clinical research with psychedelics,” he added, “exploring both how to optimize their therapeutic potential but also trying to get a better understanding of the range of medical effects, which may be problematic… There’s still some questions that need to be answered.”